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The NOD Idd9 Genetic Interval Influences
the Pathogenicity of Insulitis and Contains
Molecular Variants of Cd30, Tnfr2, and Cd137
flammatory cells. For example, accumulation of T cells
within the thyroid does not require the NOD MHC. In
fact, the thyroid inflammation is more pronounced in the
presence of the H2h4 MHC haplotype (Rasooly et al.,
1996; Hutchings et al., 1999). Thus, many of the non-
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demonstrated that alleles of at least three B10 genes,
In our initial genome scan, we obtained evidence for
Idd9.1, Idd9.2, and Idd9.3 are required to produce Idd9-
several genes that were only linked to diabetes, not to
mediated diabetes resistance. Candidate genes with insulitis. We now provide evidence that one of these,
amino acid differences between the NOD and B10 Idd9 on chromosome 4, is a true locus. The B10 allele
strains have been localized to the 5.6 cM Idd9.2 interval of Idd9 does not prevent the development of insulitis but
(Tnfr2, Cd30) and to the 2.0 cM Idd9.3 interval (Cd137). does prevent the development of infiltrates expressing
cytokines associated with b cell destruction such as
Introduction IFNg and TNFa. Insulitis in Idd9 mice is instead character-
ized by the presence of cells expressing CD30 and secret-
The NOD mouse spontaneously develops type 1 diabe- ing IL-4. The Idd9 resistance phenotype contrasts sharply
tes as well as other autoimmune syndromes such as with that of NOD mice protected by a set of linked resis-
inflammation of the thyroid, submandibular, and lacrimal tance alleles on chromosome 3 (Idd3, Idd17, Idd10, and
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dent diabetes. However the non-MHC genes present on also provide evidence that the Idd9 locus is actually
the NOD background are responsible for the breakdown composed of at least three separate Idd loci: Idd9.1,
of self-tolerance and the abnormal accumulation of in- Idd9.2, and Idd9.3. In the genetic interval containing
Idd9.2 and Idd9.3, three variant TNFR family members
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Figure 1. NOD.B10 Idd9 Mice Are Protected from Diabetes
Female (A) and male (B) NOD, NOD.B10 Idd9, and (NOD 3 NOD.B10
Idd9)F1 mice were monitored for the development of diabetes for
210 days. For females, comparisons of the 7 month cumulative
diabetes frequencies of the two parental strains as well as the F1
strain versus both parental strains had p values of ,1024 (Fisher's
exact test). For males, comparison of the two parental strains had
a p value of ,1024. The F1 differed from NOD with a p value of
0.0005 and from the NOD.B10 Idd9 strain with a p value of 0.0031.
Figure 2. NOD.B10 Idd9 Mice Are Protected from Diabetes but NotResults
from the Development of Insulitis
(A) Insulitis is more prevalent in NOD.B10 Idd9 mice than in NOD.B6NOD.B10 Idd9 Mice Are Highly Protected
Idd3 Idd17 Idd10 Idd18 mice. Insulitis was assessed in nondiabetic
from Spontaneous Diabetes mice. Each animal received one of the following scores: none (all
Earlier linkage studies with the B10 and B6 strains dem- islets observed are free of insulitis), mild (less than 10% of the islets
are infiltrated), moderate (10%±50% of the islets are affected), oronstrated that a gene, Idd9, located in the distal portion
extensive (greater than 50% of the islets have insulitis). Data andof chromosome 4 in the NOD strain, contributes to the
observations for the NOD.B6 Idd3 Idd17 Idd10 Idd18 mice weredevelopment of spontaneous diabetes (Ghosh et al.,
previously described (Wicker et al., 1994b).1993; Rodrigues et al., 1994). With the eventual goal of
(B) Massive insulitis in an islet from a 7-month-old male NOD.B10
characterizing and fine-mapping Idd9, we developed Idd9 mouse is shown after formalin fixation and hematoxylin and
a congenic strain on the NOD background containing eosin staining (3100).
approximately 48 cM of introgressed B10-derived ge-
netic material (Table 1). Female and male NOD.B10 Idd9
mice were monitored for the development of diabetes Insulitis in NOD.B10 Idd9 Mice
and were found to be highly resistant (p , 1024) to To determine if the protection from diabetes in the
the development of disease as compared to the NOD NOD.B10 Idd9 strain correlated with a reduction in insu-
parental strain (Figure 1). Thus, the existence of a diabe- litis, as was seen with the NOD.B6 Idd3 Idd17 Idd10
tes resistance gene, Idd9, on chromosome 4 was con- Idd18 strain (Wicker et al., 1994b), pancreata were exam-
firmed by these observations. ined histologically at various ages from both female and
The level of diabetes resistance observed in the male NOD.B10 Idd9 mice. Almost all of the pancreata
NOD.B10 Idd9 strain is profound and similar to that examined from young (3 months of age) and old (7±9
reported in the NOD.B6 Idd3 Idd10 Idd18 and NOD.B6 months of age) NOD.B10 Idd9 mice of both sexes had
Idd3 Idd17 Idd10 Idd18 strains: 3%±7% in females and mild to extensive insulitis (Figure 2A). In fact, the insulitis
0%±2% in males (Wicker et al., 1994b; Podolin et al., seen with hematoxylin and eosin staining of NOD.B10
1997). Resistance to diabetes was found to be a semi- Idd9 pancreata could not be distinguished from that
dominant trait, since both male and female (NOD 3 in NOD mice (Figure 2B). In contrast to the combined
NOD.B10 Idd9)F1 mice were partially protected from activities of Idd3, Idd17, Idd10, and Idd18, which reduce
disease and were significantly different from both paren- the occurrence and severity of insulitis (Figure 2A), dia-
betes resistance mediated by Idd9 must function on thetal strains (Figure 1).
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Figure 3. Immunohistochemical Analysis of
NOD and NOD.B10 Idd9 Pancreata
An infiltrated NOD islet (A, D, G, and J) and
heavily (B, E, H, and K) and mildly (C, F, I,
and L) infiltrated NOD.B10 Idd9 islets were
assessed for the indicated cytokines and cell
surface marker (3200). This figure is repre-
sentative of ten nondiabetic female mice of
each strain examined from 10 to 20 weeks of
age. Within each strain there was no age-
dependent variation of cytokine or CD30 ex-
pression observed.
pathogenicity of the insulitis or the resistance of the b shown), did differ between the two strains. IL-1, IL-2,
IL-5, and IL-10 were not detected in either strain.cells to immune destruction.
Islet infiltrates from both a heavily (Figures 3B, 3E,
3H, and 3K) and a mildly (Figures 3C, 3F, 3I, and 3L)
Qualitative Differences in the Inflammatory Cells infiltrated NOD.B10 Idd9 islet were compared to an in-
within NOD and NOD.B10 Idd9 Islets sulitis-positive NOD islet (Figures 3A, 3D, 3G, and 3J). In
In order to distinguish between these possible mecha- the NOD islets IFNg (Figures 3A±3C) and TNFa (Figures
nisms of action of Idd9-mediated protection in the islets, 3D±F) are preferentially expressed (Figures 3A and 3D),
the expression of various cell surface receptors and while IL-4 (Figures 3G±3I) is the prominent cytokine in
cytokines was examined in the pancreatic infiltrates of the infiltrating cells present in the NOD.B10 Idd9 islets
NOD.B10 Idd9 and NOD mice. Pancreata from ten nondi- (Figures 3H and 3I). It is particularly striking that even
abetic female mice of each strain ranging in age from 10 when very few infiltrating cells are present in NOD.B10
to 20 weeks were assessed. No significant differences Idd9 islets, IL-4 is still the prominent feature (Figure 3I).
between the two strains were observed in the numbers CD30 is a TNFR family member encoded within the Idd9
of CD4-, CD8-, or B220-positive cells present in the genetic region (Table 1) that is preferentially upregulated
insulitic lesions (data not shown). CD4-positive cells in cultured IL-4-secreting Th2 cells (Nakamura et al.,
constituted the most abundant cell type in both strains. 1997a, 1997b) and appears to play a role in protection
Equivalent expression of several adhesion molecules from diabetes mediated by CD8 T cells (Kurts et al.,
was observed for the two strains. ICAM-1 was ex- 1999). A comparison of CD30 expression (Figures 3J±3L)
pressed by endothelial cells and leukocytes. ICAM-2 with IL-4- and IFNg-producing cells within the islets
and PECAM-1 were observed on all endothelial cells, showed a pattern nearly identical to that observed with
whereas VCAM-1 was expressed on a subset of endo- IL-4: preferential expression in the NOD.B10 Idd9 islets
thelial cells. P-selectin and E-selectin were not observed (Figures 3K and 3L). The differential expression of CD30
(data not shown). In contrast, expression of CD30, IL-4, and IL-4 versus IFNg and TNFa in the NOD and NOD.B10
Idd9 infiltrated islets was seen in all mice and was notIFNg, and TNFa (Figure 3), plus IL-13 and TGFb (not
Immunity
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Table 1. Genetic Characterization of Idd9 Congenic Strains
NOD.B10 NOD.B10 NOD.B10 NOD.B10 NOD.B10 NOD.B10 NOD.B10
Marker cMa Gene Idd9 Idd9R28 Idd9R11 Idd9R15 Idd9R38 Idd9R35 Idd9R73
D4Mit82 NOD NOD NOD NOD NOD NOD NOD
D4Mit27 3.3b B10 NOD NOD NOD NOD NOD NOD
D4Mit28 10.9b B10 B10 NOD NOD NOD NOD NOD
Jak1c ± ± ± ± ± ± ±
D4Mit31 6.3 (43/682) B10 B10 NOD NOD NOD NOD NOD
D4Mit72 8.7 (59/682) B10 B10 NOD NOD NOD NOD NOD
D4Nds20 1.0 (7/682) Lck B10 B10 nd nd nd nd nd
D4Mit69 4.7 (32/682) B10 B10 NOD NOD NOD NOD NOD
D4Mit251 0 (0/368) nd B10 NOD nd NOD NOD NOD
D4Nds23 4.1 (15/368) CD30 B10 B10 B10 B10 B10 NOD NOD
D4Mit233 0 (0/368) Tnfr2 B10 B10 B10 B10 B10 NOD NOD
D4Mit285 0.3 (2/682) nd B10 B10 B10 B10 NOD NOD
D4Mit310 0.6 (4/682) nd B10 B10 B10 B10 NOD NOD
D4Mit127 0.4 (3/682) B10 B10 B10 B10 B10 NOD NOD
D4Mit226 0.2 (1/554) nd nd nd B10 B10 B10 NOD
D4Mit33 0 (0/554) B10 B10 B10 B10 B10 B10 NOD
D4Mit190 0 (0/554) nd nd nd B10 B10 B10 NOD
D4Nds24 0 (0/554) Cd137 B10 B10 B10 B10 B10 B10 NOD
D4Mit63 0 (0/554) nd nd nd B10 B10 B10 NOD
Wsl1d ± ± ± ± ± ± ±
D4Mit42 1.8 (10/554) nd nd nd NOD NOD B10 B10
D4Mit180 0.2 (1/554) B10 B10 B10 NOD NOD B10 B10
D4Mit59 5.5b NOD NOD NDO NOD NOD NOD NOD
Ox40d ± ± ± ± ± ± ±
a Intermarker distance in centimorgans (number of recombinants/total meioses typed).
b Distance from MIT database.
c Position determined from Mouse Genome Database.
d Position determined by typing the T31 mouse radiation hybrid panel.
nd, not determined; ±, no variant marker available.
affected by age. IL-13 and TGFb were also observed in congenic interval between the markers D4Mit251and
D4Mit59 (Table 1). The development of diabetes in co-infiltrated islets of NOD.B10 Idd9 but not of NOD mice
(data not shown). Thus, the protection afforded by the horts of female mice from each strain was assessed over
a period of 7 months (Figure 4). The congenic intervals ofB10 Idd9 genetic region is consistent with an alteration
of the pathogenicity of the insulitis. strains R28 and R11 both conferred significant protec-
tion from diabetes (p , 0.0001 for both strains compared
to the NOD parental strain). However, the R28 strain wasComplete Protection from Spontaneous Diabetes
in NOD Congenic Mice with Resistance
Alleles on Both Chromosomes 3 and 4
Given the highly significant protection from diabetes
afforded by introgression of non-NOD DNA from chro-
mosome 3 (NOD.B6 Idd3 Idd17 Idd10 Idd18) or chromo-
some 4 (NOD.B10 Idd9), we developed a congenic strain
that combines these two protective regions: NOD.B6
Idd3 Idd17 Idd10 Idd18 B10 Idd9 (triple congenic). There
was no spontaneous diabetes observed in more than
250 female and male triple congenic mice followed for
7 months. A subgroup of mice (n 5 133) aged to 12
months also did not develop diabetes. Despite the lack
of diabetes, a small number of NOD.B6 Idd3 Idd17 Idd10
Idd18 B10 Idd9 mice developed insulitis (10%, n 5 20).
The Original Idd9 Effect Is Due to the Combined
Action of at Least Three Loci
To refine the map location of Idd9, we bred two series
of subcongenic strains. The first set of subcongenic
strains, NOD.B10 Idd9R28 (R28) and NOD.B10 Idd9R11
(R11), was derived from the original NOD.B10 Idd9 strain
(Table 1). The R28 strain has a 44.7 cM congenic interval Figure 4. Localization of Idd9.1, Idd9.2, and Idd9.3
between but not including the microsatellite markers Subcongenic strains were developed and assessed for the develop-
ment of diabetes.D4Mit27 and D4Mit59. The R11 strain has a 13.1 cM
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significantly more protected than the R11 strain (p ,
0.0001 for R28 versus R11), implying that the R28 con-
genic interval contains at least one additional protective
locus as compared to the R11 interval. This locus,
Idd9.1, must lie in the 35.7 cM interval between but
not including the microsatellite markers D4Mit27 and
D4Mit251 (Table 1).
A second set of Idd9 subcongenic mice was devel-
oped from the R11 strain. The strains NOD.B10 Idd9R15
(R15) and NOD.B10 Idd9R38 (R38) have congenic inter-
vals of 7.4 cM between the microsatellite markers
D4Mit251 and D4Mit42, the NOD.B10 Idd9R35 (R35)
strain has a congenic interval of 7.7 cM between the
markers D4Mit127 and D4Mit59, and the NOD.B10
Idd9R73 (R73) strain has a congenic interval of 7.5 cM
between the markers D4Mit63 and D4Mit59 (Table 1).
The development of diabetes in female mice from each
of these strains is shown in Figure 4. The R15 and R38
strains fully recapitulate the diabetes protection seen in
the parental R11 strain mapping the Idd locus contained
within this congenic interval to proximal of D4Mit42. This
Figure 5. Variant Candidate Genes Located in the Idd9.2 and Idd9.3mapping data is confirmed by the reciprocal R73 strain,
Intervalswhich is NOD derived between the markers D4Mit251
Variants of Cd30 (A), Tnfr2 (B), and Cd137 (C). B10 to NOD changesand D4Mit42 and has an NOD-like frequency of diabetes
are noted below each diagram.(Figure 4). The R35 strain, while significantly protected
from diabetes development (p 5 0.0026 versus NOD),
is significantly less protected than the R15, R38, or R11
was excluded as a candidate for any of the Idd9 loci asstrains (p , 0.0001, p 5 0.0005, and p 5 0.0024, respec-
it maps distal to D4Mit59 and therefore outside of thetively). Thus, the diabetes protection conferred by the
original long Idd9 congenic interval (data not shown).R11 congenic interval is most likely due to the interaction
of at least two loci: Idd9.2, which maps to the 5.6 cM
interval between the markers D4Mit251 and D4Mit226, Cell Surface Expression of TNFR
and Idd9.3, which maps to the 2.0 cM region between Superfamily Members
D4Mit127 and D4Mit42 (Table 1). Since sequence variation has been observed between
the NOD and B10 genes encoding CD30, TNFR2, and
CD137, we compared the cell surface expression ofA Cluster of Genes Encoding TNFR Superfamily
Members Maps to the Idd9.2/Idd9.3 Interval these molecules on CD4 and CD8 splenic T cells follow-
ing activation with anti-CD3. Spleen cells obtained fromCd30, Tnfr2, Cd137 (4±1bb), Wsl1, and Ox40 are mem-
bers of the TNFR superfamily that contribute to the acti- the NOD and R28 strains, which have the NOD and B10
alleles of Cd30, Tnfr2, and Cd137, respectively, werevation and/or apoptosis of cells and have been mapped
to distal chromosome 4. Genotyping the Idd9 sub- cultured with anti-CD3 using Th1 or Th2 conditions. After
72 hr of stimulation, cell surface expression of CD137congenic strains positions the CD30 and TNFR2 genes
in the 5.6 cM Idd9.2 interval (Table 1). Both the CD30 and CD30 was optimal with Th2 culture conditions in
both strains. TNFR2 expression was equivalent using(Siegmund et al., 2000) and TNFR2 (Powell et al., 1994)
genes contain sequence variants that give rise to amino either Th1 or Th2 conditions in both strains. Representa-
tive profiles for CD137 and TNFR2 expression on anti-acid variation between the NOD and B10 forms of their
respective proteins (Figure 5). This coding variation CD3-stimulated CD8 cells are shown in Figure 6A. A
complete profile of CD30 expression on activated CD4makes both genes candidates for Idd9.2. Sequencing
of the CD137 gene in the present report identified three and CD8 cells is shown in Figure 6B. Interestingly, CD30
is highly expressed in infiltrated islets from diabetes-coding variants between B10 and NOD, a valine to ala-
nine substitution at position 24, a leucine to proline sub- resistant NOD.B10 Idd9 mice (Figures 3K and 3L) but
not from NOD mice (Figure 3J). However, CD4 and CD8stitution at position 211, and the insertion of an alanine
in NOD between amino acids 174 and 175 (Figure 5). Th2-polarized cells from both strains express CD30 (Fig-
ure 6B) and secrete IL-4 following recall at day 4 withAnalysis of the Idd9 congenic strains places the CD137
gene within the 2.0 cM Idd9.3 interval (Table 1), making anti-CD3 (data not shown). In contrast, CD4 and CD8
Th1-polarized cells from both strains express little orit a candidate for this locus. The WSL1 gene maps to
the distal boundary of the Idd9.3 interval between the no CD30 (Figure 6B) and secrete no IL-4 upon recall
challenge (data not shown). Significant levels of IL-4 aremicrosatellite markers D4Mit63 and D4Mit42 (Table 1).
Sequencing of WSL1 identified no nucleotide variation only observed in the islet infiltrates of NOD.B10 Idd9
mice (Figures 3H and 3I). This suggests that the relativelybetween NOD and B10 within either the coding region
or the putative promoter (data not shown). The absence low level of CD30 expression in the cellular infiltrates
of NOD islets (Figure 3G) is due to insufficient levelsof any sequence variation between NOD and B10 makes
Wsl1 an unlikely candidate for Idd9.3. The OX40 gene of IL-4.
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based on linkage mapping results. The observation of
disease protection in such congenic strains provides
evidence of the existence of individual Idd loci. More-
over, the development of congenic strains facilitates
functional analyses of Idd loci, either in isolation or in
specific combinations (Serreze et al., 1994, 1998; Wicker
et al., 1994b; Lord et al., 1995; Yui et al., 1996; Denny
et al., 1997; Podolin et al., 1997, 1998; Melanitou et al.,
1998; Brodnicki et al., 2000). We have now constructed
and analyzed the phenotypes of congenic strains car-
rying diabetes-resistance alleles on chromosomes 3 and
4 (Wicker et al., 1994b; Lord et al., 1995; Denny et al.,
1997; Podolin et al., 1997, 1998; Lyons et al., 2000).
Results from these analyses clearly demonstrate that
two mechanisms of protection from naturally occurring
autoimmune b cell destruction can be defined. The first,
which is a characteristic of the loci on chromosome 3,
results in a severe reduction of inflammatory cells in
islets. The second, observed with the loci on chromo-
some 4, does not reduce the number of infiltrating cells
but causes a change in the cytokine profiles and patho-
genic properties of the infiltrate.
The finding that the diabetes protection afforded by
Idd9 is associated with the accumulation of IL-4-produc-
ing cells in the islets is reminiscent of other studies in
which IL-4 is associated with a nonpathogenic outcome.
For example, in orally tolerized NOD mice, disease sup-
pression is accompanied by an increase in IL-4- and a
decrease in IFNg-producing cells (Hancock et al., 1995;
Ploix et al., 1998). In addition, long-term survival of allo-
geneic and xenogenic vascularized grafts induced by
immunosuppression is associated with a Th2-like cellu-
lar response, whereas rejected grafts contain a Th1 cell
infiltrate (Mottram et al., 1995; Bach et al., 1997). While
it is likely that these models reflect different mechanisms
of initiating immune regulation, it is clear that the ulti-
mate accumulation of IL-4-producing cells is associated
with disease protection. In light of the association of
IL-4 production with Idd9-mediated diabetes protection,
it is particularly striking that transgenic production of
IL-4 in the islet b cell eliminates diabetes and insulitis
in NOD mice (Mueller et al., 1996).
In the current study, subcongenic analysis of the Idd9
region has demonstrated that at least three loci are
Figure 6. Expression of Molecules Encoded by Variant Candidate responsible for the B10 Idd9-mediated protection from
Genes diabetes: Idd9.1, Idd9.2 and Idd9.3. In addition, we have
(A) Cell surface expression of TNFR2 and CD137 on activated CD8 delineated the genetic intervals containing Idd9.2 and
T cells. Spleen cells obtained from NOD and NOD.B10 Idd9R28 Idd9.3 to 5.6 and 2.0 cM, respectively. These intervals
mice were stimulated with anti-CD3 for 72 hr using Th2 conditions.
are now sufficiently small to sequence biologically rele-Profiles display cell surface expression of TNFR2 and CD137 (versus
vant candidate genes contained within the regions (Ly-isotype controls in each profile) on gated CD8 cells. The data are
ons and Wicker, 1999). To this end, we have found thatrepresentative of two experiments.
(B) Cell surface expression of CD30 on CD4 and CD8 T cells. NOD the coding regions of the tightly linked genes Cd30 and
and NOD.B10 Idd9R28 spleen cells were stimulated under Th1 or Tnfr2 vary between NOD and B10. We have shown pre-
Th2 conditions for 72 hr. The profiles shown are gated either on viously that the NOD allele of Tnfr2 varies at five amino
CD4 or CD8 cells as indicated and display cell surface expression acids from the B10 and B6 allele (Powell et al., 1994),of CD30 (versus an isotype control). The data are representative of
and we have recently found that the CD30 gene has fourtwo experiments.
amino acid differences between NOD and B10 (Sieg-
mund et al., 2000). Some of the coding differences are
Discussion not conservative and may influence trimerisation of
these TNFR family members. Among other possibilities,
The NOD mouse model of human type 1 diabetes is suboptimal association of TNFR chains could alter cell
complex, involving many genes and biochemical path- surface stability, binding to the cognate TNF family li-
ways. In order to analyze the natural disease process gand, or association of the cytoplasmic domain with
TRAF proteins, which may in turn affect downstreamin NOD mice, congenic strains have been produced
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signaling from the receptor. Thus, Cd30 and Tnfr2, (Lyons et al., 2000). However, when isolated within small
whose protein products have been shown to mediate congenic intervals, other alleles contributing to resis-
cell death (Amakawa et al., 1996; Wong and Choi, 1997), tance such as Idd10 and Idd18 are much less potent
are both candidates for Idd9.2. (Podolin et al., 1998) than the resistance allele at Idd3.
Interestingly, a recent study demonstrated that CD30 Although individually their effects are limited, the combi-
is essential for controlling the diabetogenicity of CD8 T nation of Idd3, Idd10, and Idd18 provides almost com-
cells in a transgenic model of autoimmune diabetes plete protection from diabetes (Wicker et al., 1994b). A
(Kurts et al., 1999). CD302/2 CD8 cells were shown to similar picture has emerged in the current study of the
have a much higher proliferative potential in vivo than Idd9 region. At least three genes contribute to the nearly
wild-type CD8 cells. Since CD8 T cells are critical to complete protection from disease seen when all three
the initiation and progression of diabetes in NOD mice alleles are present in a homozygous state. The existence
(Wicker et al., 1994a; Serreze et al., 1997), the presence of two sets of linked resistance genes, one set on chro-
of a variant CD30 gene within the Idd9.2 interval is partic- mosome 3 and another set on chromosome 4, suggests
ularly intriguing. Given these recent observations by that sets of linked alleles may have been selected to
Kurts et al. (1999), it is possible that a major protective provide a particular advantage to some infectious agent.
effect of IL-4 production in the pancreas is its ability to Interestingly, these two sets of resistance genes medi-
upregulate CD30 expression (Figures 3K and 3L). Rapo- ate protection in very different ways, suggesting that
port et al. (1993) have reported defective IL-4 secretion there may be several mechanisms that could be targeted
from concanavalin A±stimulated thymocytes in NOD in modulating the progression of autoimmunity. The mo-
mice, which could account for the reduced IL-4 levels lecular and cellular basis of such potent disease protec-
seen in the parental strain. tion will contribute to the understanding of autoimmune
Cd137, which is also a TNFR family member, also disease pathogenesis and the development of therapeu-
varies in the coding region between NOD and B10. Most tic approaches. Such therapies may require the com-
noteworthy is a nonconservative leucine to proline alter- bined targeting of several genetically distinct pathways.
ation in the cytoplasmic domain. Such a change could
alter the function of the trimeric receptor as outlined
Experimental Procedures
above, thereby making Cd137 a candidate gene for
Idd9.3. In contrast to TNFR2 and CD30, CD137 signaling Mice
mediates positive stimulation in both CD4 and CD8 cells NOD.B10 Idd9 mice were developed by backcrossing C57BL/10
mice purchased from the Jackson Laboratory (Bar Harbor, ME) to(Shuford et al., 1997; Mittler et al., 1999). These three
NOD/MrkTacfBR mice obtained from Taconic Farms (Germantown,candidate genes along with the genes underlying Idd9.1
NY) with selection for the described region on chromosome 4 (Tablemay represent autoimmunity loci, since other autoim-
1). Mice used in this study were from the N9F2±4 generations.
mune diseases have been linked to this region (Vyse Founders of the NOD.B10 Idd9 strain were tested for the presence
and Todd, 1996). Loci controlling systemic lupus erythe- of B10 chromosome segments throughout the genome using a panel
matosus (Nba1) and thymectomy-induced autoimmune of microsatellite markers that differentiate NOD and B10 genomic
segments (Lord et al., 1995). All non±chromosome 4 markers exam-gastritis (EAG, Gasa1) have been mapped to Idd9.1
ined were of NOD origin in the NOD.B10 Idd9 strain. The NOD.B10(Drake et al., 1994; Silveira et al., 1999), and loci influenc-
Idd9R11 (N12F2±4) and NOD.B10 Idd9R28 (N12F2±4) subcongenicing autoimmune hemolytic anemia (Aia1) and EAG
strains were developed from the NOD.B10 Idd9 strain, and the(Gasa2) have been mapped to the Idd9.2 and Idd9.3
NOD.B10 Idd9R15 (N14F2±4), NOD.B10 Idd9R35 (N14F2±4),
intervals (Knight and Adams, 1981; Silveira et al., 1999). NOD.B10 Idd9R38 (N14F2±4), and NOD.B10 Idd9R73 (N14F2±4)
A locus influencing susceptibility to experimental auto- strains were developed from the NOD.B10 Idd9R11 strain, essen-
immune encephalomyelitis has also been localized to tially as described previously (Podolin et al., 1997).
To produce the NOD.B10 Idd9 B6 Idd3 Idd10 strain, mice fromthe distal region of chromosome 4 (Encinas et al., 1996).
the NOD.B6 Idd3 Idd10 (N6F9) strain (termed NOD.B6Il2-Tshb in WickerIdd11, defined originally in an outcross between the
et al., 1994b), which has approximately 40 cM of B6 DNA fromNOD and B6 strains, has been recently shown by con-
chromosome 3 introgressed onto the NOD background, were inter-genic analysis to be localized to a 13 cM interval on
crossed with NOD.B10 Idd9 N9F4 mice. Progeny having the non-
chromosome 4 (Brodnicki et al., 2000). This interval is NOD regions on both chromosomes 3 and 4 were selected.
contained entirely within the Idd9.1 segment delineated
in the current study. While these results are consistent
Assessment of Diabeteswith Idd11 and Idd9.1 being the same gene, B6 and B10
Elevated urinary glucose was detected using Diastix (Miles, Elkhart,
mice differ in more than one gene within this interval IN). Animals were classified as diabetic when urinary glucose was
(McClive et al., 1994; Morahan et al., 1994), and hence at least 500 mg/dl. Diabetic mice also exhibited polydipsia, polyuria,
the Idd9.1 segment could contain more than one Idd and weight loss.
locus. Further refinement of the location of both loci is
required to prove this hypothesis. Histology
The NOD mouse genetic background predisposes to Pancreata were fixed in 10% bufferred formalin and processed for
autoimmune inflammation and diabetes and appears to paraffin embedding. Tissue sections (5 mm) were stained with hema-
toxylin and eosin and microscopically evaluated for the presencecontain no major resistance alleles. Susceptibility alleles
of mononuclear cell infiltrates. Two noncontiguous sections of eachof many loci combine to exceed a disease threshold for
pancreas were examined. To evaluate islets for leukocyte infiltrationwhich the introduction of only one resistance allele (in
and differential cytokine expression, pancreata were quick frozen
the homozygous state) can cause the majority of mice in liquid nitrogen and processed as described for the following: cell
to fall below this threshold and become resistant to markersÐCD4, CD8, CD30, B220; adhesion moleculesÐP-selectin,
disease. Such a potent effect was observed when the E-selectin, ICAM-1, ICAM-2, PECAM-1, and VCAM-1; and cyto-
kinesÐIL-1, IL-2, IL-4, IL-5, IL-10, IL-13, IFNg, TNFa, and TGFbB6 allele of Idd3 was introgressed onto the NOD genome
Immunity
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(Hancock et al., 1995), using mAbs purchased from PharMingen disease in (NZB x NZW)F1 mice. Proc. Natl. Acad. Sci. USA 91,
4062±4066.(San Diego, CA).
Encinas, J.A., Lees, M.B., Sobel, R.A., Symonowicz, C., Greer, J.M.,
Statistical Analysis Shovlin, C.L., Weiner, H.L., Seidman, C.E., Seidman, J.G., and Kuch-
Fisher's exact test was used to compare the 7 month cumulative roo, V.K. (1996). Genetic analysis of susceptibility to experimental
diabetes frequencies of the NOD congenic mice. Comparisons giv- autoimmune encephalomyelitis in a cross between SJL/J and B10.S
ing p values greater less than 0.05 were considered to be significant. mice. J. Immunol. 157, 2186±2192.
To compare the frequency of diabetes in subcongenic strains,
Encinas, J.A., Wicker, L.S., Peterson, L.B., Mukasa, A., Teuscher,
Kaplan-Meier survival analysis was performed using the Log-Rank
C., Sobel, R., Weiner, H.L., Seidman, C.E., Seidman, J.G., and Kuch-
test.
roo, V.K. (1999). QTL influencing autoimmune diabetes and enceph-
alomyelitis map to a 0.15- cM region containing Il2. Nat. Genet. 21,
Candidate Gene Sequencing and Mapping 158±160.
PCR primer pairs flanking each exon of Cd137 and Wsl1 were de-
Ghosh, S., Palmer, S.M., Rodrigues, N.R., Cordell, H.J., Hearne,signed based on their genomic sequence. Following amplification,
C.M., Cornall, R., Prins, J.-B., McShane, P., Lathrop, G.M., Peterson,PCR products were sequenced directly using either a BigDye termi-
L.B., et al. (1993). Polygenic control of autoimmune diabetes innator cycle sequencing kit (PE Biosystems, Warrington, UK) or Bod-
nonobese diabetic mice. Nat. Genet. 4, 404±409.ipy Dye primers (Metzker et al., 1998). Cd137 was mapped by typing
Hancock, W.W., Polanski, M., Zhang, J., Blogg, N., and Weiner, H.L.D4Nds24 on 277 F2 progeny of crosses between NOD and NOD.B10
(1995). Suppression of insulitis in non-obese diabetic (NOD) miceIdd9R28 or NOD.B10 Idd9R11. Wsl1 and Ox40, for which no poly-
by oral insulin administration is associated with selective expressionmorphic markers exist, were mapped relative to the other markers
of interleukin-4 and -10, transforming growth factor-beta, and pros-using the T31 mouse hamster radiation hybrid panel (McCarthy et
taglandin-E. Am. J. Pathol. 147, 1193±1199.al., 1997).
Hutchings, P.R., Verma, S., Phillips, J.M., Harach, S.Z., Howlett, S.,
Induction and Assessment of Cell Surface Expression and Cooke, A. (1999). Both CD4(1) T cells and CD8(1) T cells are
of TNFR2 and CD137 required for iodine accelerated thyroiditis in NOD mice. Cell. Immu-
Spleen cells (0.6 3 106/ml) were cultured for 72 hr using standard nol. 192, 113±121.
culture conditions (Chen et al., 1994) with anti-CD3 (500 ng/ml 2C11), Knight, J.G., and Adams, D.D. (1981). Genes determining autoim-
2 ng/ml IL2, and either 20 ng/ml IL4 (Th2 conditions) or 2 ng/ml mune disease in New Zealand mice. J. Clin. Lab. Immunol. 5,
IL12 and 2 mg/ml anti-IL4 (Th1 conditions). Cells were washed and 165±170.
incubated with FITC-conjugated anti-CD4 (RM4±5), APC-conju-
Kurts, C., Carbone, F.R., Krummel, M.F., Koch, K.M., Miller, J.F.,gated anti-CD8 (53±6.7), and one of the following PE conjugates:
and Heath, W.R. (1999). Signalling through CD30 protects againstanti-CD137 (1AH2) or its isotype control (R3±34) followed by PE-anti-
autoimmune diabetes mediated by CD8 T cells. Nature 398, 341±344.rat Ig (RG11/39.4) or PE-conjugated anti-TNFR2 (HM102, CALTAG,
Lord, C.J., Bohlander, S.K., Hopes, E.A., Montague, C.T., Hill, N.J.,Burlingame, CA) or its PE-conjugated isotype control (R35±95). Un-
Prins, J.-B., Peterson, L.B., Wicker, L.S., Todd, J.A., and Denny, P.less otherwise noted, all cytokines and antibodies were obtained
(1995). Mapping of the diabetes polygene Idd3 on mouse chromo-from PharMingen (San Diego, CA). Labeled cells were analyzed by
some 3 using novel congenic strains. Mamm. Genome 6, 563±570.flow cytometry (FACStar PLUS, BD Immunocytometry Systems, San
Jose, CA). Lyons, P.A., and Wicker, L.S. (1999). Localising polygenes in the
NOD mouse model of type 1 diabetes. In Genetics in Autoimmunity,
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